IN B007
Alternative Names: IN-B007Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator HK inno.N
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Cancer in South Korea
- 30 Nov 2020 IN B007 is available for licensing as of 30 Nov 2020. http://www.inno-n.com/eng/business/out_licensing.asp (HK inno.N Website, January 2021)
- 30 Nov 2020 Preclinical trials in Cancer in South Korea (unspecified route) before November 2020 (HK inno.N pipeline, January 2021)